Aspire Biopharma Holdings (ASBP) Gross Margin (2025 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Gross Margin came in at 47.68% in Q2 2026, down 335.09% quarter-over-quarter from 20.28% in Q1 2026.
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Gross Margin (2025 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Gross Margin for 2 consecutive years, with 47.68% the latest figure, recorded in Q2 2026.
- On a quarterly basis, Gross Margin changed N/A year-over-year to 47.68% in Q2 2026; TTM through Jun 2026 was 25.04%, a N/A change from a year earlier, with the FY2025 full-year figure at 1.87%, changed N/A from the prior year.
- Gross Margin was 47.68% for Q2 2026 at Aspire Biopharma Holdings, down from 20.28% in the prior quarter.
- Over five years, Gross Margin peaked at 45.54% in Q3 2025 and troughed at 47.68% in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 91.59% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 35.86% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 90.43% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 71.60% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 80.31% |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 | -47.68% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -47.68% |
| Mar 31, 2026 | 20.28% |
| Dec 31, 2025 | -23.47% |
| Sep 30, 2025 | 45.54% |